Bayer attributes improved ESG ratings to investor dialogue

German pharma and life sciences giant says changes and disclosure prompted by investor dialogue has improved its investability and ESG ratings.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.